

News Release

HYDERABAD, INDIA (29 Jan 2026) - Suven Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter and nine months ended 31 Dec 2025. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 29 Jan 2026 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			Period ended		Year ended
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
Revenue	55.83	46.97	32.40	127.47	148.63	175.53
R&D and Operational expenses	1,061.59	806.90	408.16	2,394.65	1,271.42	1,724.29
Depreciation and Amortisation	13.46	13.17	15.34	40.31	44.75	58.22
Finance cost	-	-	0.08	-	0.47	0.47
Total expenses	1,075.05	820.07	423.57	2,434.96	1,316.63	1,782.98
Exceptional items (insurance claim received)	-	-	-	-	-	-
Tax	-	-	-	-	-	-
Profit/(Loss) After Tax for the period/year	(1,019.22)	(773.10)	(391.17)	(2,307.49)	(1,168.00)	(1,607.45)
Other comprehensive income	(7.51)	0.85	(0.05)	(7.17)	(0.14)	(5.83)
Total comprehensive income	(1,026.73)	(772.25)	(391.21)	(2,314.66)	(1,168.14)	(1,613.28)
Paid up equity capital	227.47	227.47	218.07	227.47	218.07	218.07
Earnings per share of Rs.1 each (EPS)	(4.55)	(3.48)	(1.79)	(10.31)	(5.36)	(7.37)

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(c) Clinical development pipeline:

- SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer's type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion of enrollment by end of calendar 2026.
- SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy by March/April 2026.
- SUVN-911 (Ropanicant) – Ongoing Phase 2B clinical study in USA is expected to be completed by July 2026.
- SUVN-D4010 (Usmarapride) – New IND submission done with FDA for Phase-2 POC (proof of concept) for the "Treatment of cognitive dysfunction in adults with major depressive disorder (MDD) and Phase 2 double blind study will start during calendar 2026.
- SUVN-I6107 – Ongoing Phase 1 study for establishing safety and pharmacokinetics will be completed by April 2026.

(d) Suven continues its R&D programs focused on Central Nervous System (CNS) disease disorders and granted 6 patents during the period covering countries Canada, EPOA, Mexico, Singapore, Sri Lanka and Thailand.

[For more information on Suven please visit our Web site at http://www.suven.com](http://www.suven.com)

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com